# HFSRT With Concurrent TMZ for Large BMs

> **NCT03778541** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 224 (estimated)

## Conditions studied

- Brain Metastases
- Chemotherapy
- Radiotherapy

## Interventions

- **DRUG:** Temozolomide
- **RADIATION:** hypofractionated radiotherapy

## Key facts

- **NCT ID:** NCT03778541
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-03
- **Primary completion:** 2022-12-03
- **Final completion:** 2022-12-03
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03778541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03778541, "HFSRT With Concurrent TMZ for Large BMs". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03778541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*